223 related articles for article (PubMed ID: 15389537)
1. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.
Di Pietro R; Zauli G
J Cell Physiol; 2004 Dec; 201(3):331-40. PubMed ID: 15389537
[TBL] [Abstract][Full Text] [Related]
2. TRAIL and apoptosis induction by TNF-family death receptors.
Wang S; El-Deiry WS
Oncogene; 2003 Nov; 22(53):8628-33. PubMed ID: 14634624
[TBL] [Abstract][Full Text] [Related]
3. TRAIL and malignant glioma.
Hawkins CJ
Vitam Horm; 2004; 67():427-52. PubMed ID: 15110189
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders.
Younes A; Aggarwall BB
Cancer; 2003 Aug; 98(3):458-67. PubMed ID: 12879461
[TBL] [Abstract][Full Text] [Related]
5. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
[TBL] [Abstract][Full Text] [Related]
6. Apo2L/TRAIL and its death and decoy receptors.
LeBlanc HN; Ashkenazi A
Cell Death Differ; 2003 Jan; 10(1):66-75. PubMed ID: 12655296
[TBL] [Abstract][Full Text] [Related]
7. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
8. Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK; Ashkenazi A
Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
[TBL] [Abstract][Full Text] [Related]
9. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
Younes A; Kadin ME
J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
[TBL] [Abstract][Full Text] [Related]
10. Death to the bad guys: targeting cancer via Apo2L/TRAIL.
Bouralexis S; Findlay DM; Evdokiou A
Apoptosis; 2005 Jan; 10(1):35-51. PubMed ID: 15711921
[TBL] [Abstract][Full Text] [Related]
11. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E
Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines.
Guseva NV; Taghiyev AF; Sturm MT; Rokhlin OW; Cohen MB
Mol Cancer Res; 2004 Oct; 2(10):574-84. PubMed ID: 15498932
[TBL] [Abstract][Full Text] [Related]
14. PKCdelta protects human breast tumor MCF-7 cells against tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis.
Zhang J; Liu N; Zhang J; Liu S; Liu Y; Zheng D
J Cell Biochem; 2005 Oct; 96(3):522-32. PubMed ID: 16114000
[TBL] [Abstract][Full Text] [Related]
15. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
Horak P; Pils D; Kaider A; Pinter A; Elandt K; Sax C; Zielinski CC; Horvat R; Zeillinger R; Reinthaller A; Krainer M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8585-91. PubMed ID: 16361541
[TBL] [Abstract][Full Text] [Related]
16. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
17. Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex.
Cha SS; Song YL; Oh BH
Vitam Horm; 2004; 67():1-17. PubMed ID: 15110168
[TBL] [Abstract][Full Text] [Related]
18. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
19. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
20. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
